Permian Resources Corporation Class A PR 深 沪
等待开盘 04-02 09:30:00 美东时间
20.60
-0.720
-3.38%
华盛通- 最 高21.37
- 今 开20.92
- 成交量 1729.84万股
- 最 低 20.335
- 昨 收 21.32
- 总市值 172.27亿
- 52周最高 21.99
- 市盈率 静 16.10
- 换手率 2.07%
- 52周最低 10.25
- 委 比 81.82%
- 总股本 8.36亿
- 历史最高 21.99
- 量 比 1.29
- 振 幅 4.85%
- 历史最低 -1.655
- 每 手 1
- 风险率 2.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
Citigroup Maintains Buy on Permian Resources, Raises Price Target to $26
Citigroup analyst Paul Diamond maintains Permian Resources (NYSE:PR) with a Buy and raises the price target from $21 to $26.
04-01 03:37
Citigroup Maintains Buy on Permian Resources, Raises Price Target to $26
Unity Software(U.US) reported fourth-quarter financial results after the market...
04-01 03:37
Google Accelerates Quantum Timeline: New Dual-Track Strategy Aims For 2030 Commercial Breakthrough
Alphabet (GOOGL) is expanding its Quantum AI program to include neutral atoms. Discover how this dual-track hardware approach and a new Boulder-based leadership team are fueling a 1.1% stock jump.
03-25 19:39
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Truist Securities Initiates Coverage On Permian Resources with Buy Rating, Announces Price Target of $24
Truist Securities analyst Gabe Daoud initiates coverage on Permian Resources (NYSE:PR) with a Buy rating and announces Price Target of $24.
03-25 00:11
Goldman Sachs Raises Oil Price Forecasts – Picks 7 Winners Among Energy Stocks
Goldman raised Brent to $100 for Q2 2026 and sees 22% average total return in top E&P names, anchored to a conservative $75/bbl mid-cycle assumption.
03-24 03:55
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics March 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Alnylam Pharmaceuticals, Cogent Biosciences and Summit Therapeutics on Monday
03-16 18:00
